Crisantaspase

CHEMBL2108931 Phase 4 Zugelassen Enzyme

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

An enzyme derived from bacteria that breaks down asparagine, an amino acid that certain cancer cells depend on for survival. It is used to treat leukemia and lymphoma, starving tumor cells of a nutrient they cannot produce on their own.

Therapeutische Bereiche

Lymphoma Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

An enzyme derived from bacteria that breaks down asparagine, an amino acid that certain cancer cells depend on for survival. It is used to treat leukemia and lymphoma, starving tumor cells of a nutrient they cannot produce on their own.

Yes, Crisantaspase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108931. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Crisantaspase auf PillFYI

Schnelldaten

Externe Links

ChEMBL CHEMBL2108931

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.